登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H20ClNO4
化学文摘社编号:
分子量:
361.82
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
苯扎贝特, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)
SMILES string
CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O
InChI key
IIBYAHWJQTYFKB-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
bezafibrate
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... PPARA(5465), PPARD(5467), PPARG(5468)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
过氧化物酶体增殖物激活受体（PPAR）是类固醇核受体超家族成员之一。苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。
Application
Bezafibrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
R Manfredi et al.
The Journal of infection, 42(3), 181-188 (2001-09-08)
To assess the correlation between antiretroviral treatment and dyslipidaemia in HIV-infected patients, and the role of bezafibrate as a lipid-lowering agent. We retrospectively compared serum lipid levels of five groups of 40 patients, each of them treated with either saquinavir
U de Faire et al.
Cardiovascular drugs and therapy, 11 Suppl 1, 257-263 (1997-05-01)
A large number of both primary and secondary preventive trials suggest that treatment of elevated plasma lipids may reduce the frequency of coronary heart disease (CHD) events. Meta-analyses indicate that for every 10% reduction of cholesterol, CHD mortality is lowered
Alexander Tenenbaum et al.
Cardiovascular diabetology, 11, 140-140 (2012-11-16)
All fibrates are peroxisome proliferators-activated receptors (PPARs)-alpha agonists with ability to decrease triglyceride and increase high density lipoprotein- cholesterol (HDL-C). However, bezafibrate has a unique characteristic profile of action since it activates all three PPAR subtypes (alpha, gamma and delta)
J P Monk et al.
Drugs, 33(6), 539-576 (1987-06-01)
Bezafibrate is a lipid-lowering drug, chemically related to clofibrate. At its recommended dosage of 200 mg 3 times daily, or alternatively 400 mg once daily as a sustained-release preparation, it produces substantial reductions in plasma triglyceride and cholesterol concentrations in
U de Faire et al.
European heart journal, 17 Suppl F, 37-42 (1996-12-01)
Current experience from coronary angiographic trials using different treatment regimens such as lifestyle changes, resins, nicotinic acid and statins, shows that progression of atheroma can be retarded, and that regression can sometimes be induced, by a marked lowering of LDL-cholesterol.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持